Ghassan K. Abou-Alfa, MD

Articles

The Future of HCC Treatment

August 9th 2023

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

Safety Profiles of Available Therapies in Advanced HCC

August 9th 2023

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Optimal Sequencing in Patients With Advanced HCC

August 3rd 2023

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

August 3rd 2023

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

July 28th 2023

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

July 28th 2023

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Treatment Approaches for Patients With Early-Stage HCC

July 19th 2023

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

July 19th 2023

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Diagnosing Patients With Hepatocellular Carcinoma

July 12th 2023

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Overview of Hepatocellular Carcinoma (HCC)

July 12th 2023

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

HCC International Clinical Trials

February 2nd 2023

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.

Novel Strategies: Combining Systemic and Local Therapies

February 2nd 2023

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints

January 26th 2023

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

Immune Checkpoint Inhibitors and Their Effects on Liver Function

January 26th 2023

Drs Abou-Alfa, Singal, and Lewandowski discuss use of immune checkpoint inhibitors and liver function.

IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC

January 19th 2023

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

Combination Therapy with Immune Checkpoint Inhibitors for HCC

January 19th 2023

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

Immune Checkpoint Inhibitors in HCC

January 12th 2023

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

The Advent of Systemic Therapy for HCC

January 12th 2023

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

Therapy for Locally Advanced HCC

January 5th 2023

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

Child-Pugh Scoring System and Liver Function Assessment

January 5th 2023

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.